Using our platform, we are developing mRNA medicines for diverse uses and delivering them to patients across the globe. We are currently focusing on 4 medical areas – infectious diseases, immuno-oncology, rare diseases and autoimmune disease.
What is a modality?
When we identify technologies that we believe could enable a new group of potential mRNA medicines with shared features, we call that group a modality. While the programs within a modality may target diverse diseases, they share similar mRNA characteristics, delivery technologies and manufacturing processes.
Systemic secreted & cell surface therapeutics
Localized regenerative therapeutics
Systemic intracellular therapeutics
Inhaled pulmonary therapeutics
We have created seven modalities to date, but we are relentlessly working to grow this number as we discover mRNA medicines.
Medical Areas of Focus
The world needs novel, innovative approaches to address both known and future infectious disease threats.
We are harnessing the body’s immune system to identify and kill cancer cells in the same way the immune system identifies and targets infections.
Personalised cancer vaccines
We are creating individualised, mRNA-based personalised cancer vaccines to deliver one custom-tailored medicine to one patient at a time.
Moderna recognises the impact of rare diseases on patients and their families, particularly when the disease lacks any effective treatment options.
Moderna has partnered with an AstraZeneca-led study to evaluate the use of an mRNA therapeutic that can help in the fight against cardiovascular disease.
We are developing several potential mRNA therapeutics that we believe have the potential to help the millions of patients battling autoimmune diseases.
¹Englands Rare Disease Action Plan. Available at
Millions of people with rare diseases to benefit from faster diagnosis and better access to treatment Last Accessed August 2022.
²British Heart Foundation Statistics. Available at
Heart Statistics- Accessed August 2022